Some disappointment today, for CSL, the old Commonwealth Serum Laboratories.

A research outcome fell flat (CSL112, a study/drug designed to reduce MACEs).

Some analysts had this in their models at 70% likelihood, others, none at all. The market was disappointed, either way, with the stock falling almost 5% (after a solid run to $300 over the past quarter).

We hold CSL at an underweight in our flagship equity portfolios (4.5%) and market weight (~7%) in one of our more concentrated portfolios.

We see it as a Growth style stock, executing well overall, and that this drug, it’s failure, is part and parcel of R&D in biotech land.

CSL will continue to innovate, and given unmet clinical needs, is highly incentivized to do so. File under “would’ve been nice, but no other major implication”.

Important Information: This document has been prepared by Aequitas Investment Partners ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of C2 Financial Services, (Australian Financial Services Licensee no. 502171), and is for distribution within Australia to wholesale clients and financial advisers only.

This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.

Please note that past performance is not a reliable indicator of future performance.

General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.

Taxation warning: Any taxation considerations are general and based on present taxation laws and may be subject to change. Aequitas is not a registered tax (financial) adviser under the Tax Agent Services Act 2009 and investors should seek tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law.